Cost-effectiveness analysis of pembrolizumab as an adjuvant treatment of early-stage non-small cell lung cancer following complete resection and platinum-based chemotherapy in Canada
Adjuvant pembrolizumab was found to be cost-effective compared to routine observation from the public healthcare payer perspective in Canada.
Authors
- Sreetama Sarkar (ORCID: https://orcid.org/0009-0009-2182-6200)
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Elizabeth Wehler (ORCID: https://orcid.org/0000-0001-5059-882X)
- Ruifeng Xu (ORCID: https://orcid.org/0000-0002-4009-5679)
- Xiaohan Hu (ORCID: https://orcid.org/0000-0002-5608-2864)
- Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
- Divya Vohra (ORCID: https://orcid.org/0000-0002-5167-2582)
- Brian M. Lang (ORCID: https://orcid.org/0000-0003-1121-5982)
- Catherine Langevin (ORCID: https://orcid.org/0000-0001-7658-1014)
- Arielle G. Bensimon (ORCID: https://orcid.org/0000-0003-1967-2045)
- Sylvi Nguyen
- Ralph P. Insinga
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Princess Margaret Cancer Centre (CA)
- MSD (Switzerland) (CH)
- Health Outcomes Solutions (United States) (US)
- MSD (Belgium) (BE)
- National Council of Applied Economic Research (IN)
- Decision Sciences (United States) (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Systématique, adaptation, évolution (FR)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1080/13696998.2025.2530862
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05